Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kammen

Showing results (341-350 of 549) with videos related to

Pageof 55
Sort By:
Canadian Prosthetics & Orthotics Journal|April 1, 2026
Corrigendum: Relative aerobic load of daily activities in individuals with lower limb amputation: A pilot studyL van Schaik, K van Kammen, S W M Huiberts, et al.
Nature|June 21, 2002
Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumoursAngeliki Malliri, Rob A van der Kammen, Kristopher Clark, et al.
Journal of Bacteriology|January 1, 1985
hisT is part of a multigene operon in Escherichia coli K-12C C Marvel, P J Arps, B C Rubin, et al.
Biochimica Et Biophysica Acta|September 7, 1988
Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated proteinP de Pagter-Holthuizen, M Jansen, R A van der Kammen, et al.
Schizophrenia Research|October 22, 2008
Semantic memory in schizophrenia: association with cell membrane essential fatty acidsRuth Condray, Jeffrey K Yao, Stuart R Steinhauer, et al.
Biological Psychiatry|March 1, 1997
Diminished cardiac vagal tone in schizophrenia: associations to brain laterality and age of onsetD Malaspina, G Bruder, G W Dalack, et al.
Schizophrenia Research|November 24, 1998
Confirmatory factor analysis of the WAIS-R in patients with schizophreniaD N Allen, S G Huegel, B E Seaton, et al.
Schizophrenia Research|September 8, 2012
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/dayHerbert Y Meltzer, Helio Elkis, Kimberly Vanover, et al.
Archives of General Psychiatry|March 1, 1982
Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine responseD P van Kammen, J P Docherty, S R Marder, et al.
Artificial Organs|August 1, 1983
Double-blind evaluation of plasmapheresis in schizophrenic patients: a pilot studyS C Schulz, D P van Kammen, R Waters, et al.
Pageof 55

Showing results (341-350 of 549) with videos related to

Sort By:
Pageof 55
Canadian Prosthetics & Orthotics Journal|April 1, 2026
Corrigendum: Relative aerobic load of daily activities in individuals with lower limb amputation: A pilot studyL van Schaik, K van Kammen, S W M Huiberts, et al.
Nature|June 21, 2002
Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumoursAngeliki Malliri, Rob A van der Kammen, Kristopher Clark, et al.
Journal of Bacteriology|January 1, 1985
hisT is part of a multigene operon in Escherichia coli K-12C C Marvel, P J Arps, B C Rubin, et al.
Biochimica Et Biophysica Acta|September 7, 1988
Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated proteinP de Pagter-Holthuizen, M Jansen, R A van der Kammen, et al.
Schizophrenia Research|October 22, 2008
Semantic memory in schizophrenia: association with cell membrane essential fatty acidsRuth Condray, Jeffrey K Yao, Stuart R Steinhauer, et al.
Biological Psychiatry|March 1, 1997
Diminished cardiac vagal tone in schizophrenia: associations to brain laterality and age of onsetD Malaspina, G Bruder, G W Dalack, et al.
Schizophrenia Research|November 24, 1998
Confirmatory factor analysis of the WAIS-R in patients with schizophreniaD N Allen, S G Huegel, B E Seaton, et al.
Schizophrenia Research|September 8, 2012
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/dayHerbert Y Meltzer, Helio Elkis, Kimberly Vanover, et al.
Archives of General Psychiatry|March 1, 1982
Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine responseD P van Kammen, J P Docherty, S R Marder, et al.
Artificial Organs|August 1, 1983
Double-blind evaluation of plasmapheresis in schizophrenic patients: a pilot studyS C Schulz, D P van Kammen, R Waters, et al.
Pageof 55